article banner
Private Equity

Trump's drug cost concern an opportunity for Indian firms

rich text with image

"If controlling cost of drugs is a priority for the new administration, US cannot write off Indian pharmaceutical products. At the price we offer, US companies cannot produce them in that country,".

Vrinda Mathur
Partner, Grant Thornton Bharat LLP

This article appeared in My Digital FC on 23rd January, 2017.